ITRM - Iterum keeps rising even as RBC analyst cautions Premier hurt by Barclays' double downgrade; and more in today's analyst action

Iterum jumps even as RBC says sulopenem may not be a “shoo-in”Iterum Therapeutics (ITRM) is extending the post-market gains with a ~18.7% rise in early hours in reaction to the FDA decision not to hold an AdCom meeting for the company’s marketing application for urinary tract infections treatment sulopenem.Despite the optimism, sulopenem may not be an easy winner, RBC Capital Markets analyst Gregory Renza wrote citing four recent AdCom cancellations where only half received approvals while the rest were turned down.In early April, Iterum sank after the company announced that the FDA needed more time to review its marketing application for sulopenem.Premier trades lower after a double downgrade at Barclays Premier Inc. (PINC) is trading ~2.0% lower in the pre-market after Barclays analysts Steve Valiquette and Jonathan Yong lowered their recommendation to underweight from overweight.Despite a positive industry view on hospital GPO business, multiple expansion for Premier shares above historical averages is unlikely, the analysts wrote.As the

For further details see:

Iterum keeps rising even as RBC analyst cautions, Premier hurt by Barclays’ double downgrade; and more in today’s analyst action